{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"SGN-30"},{"type":"LexicalVariant","name":"monoclonal antibody SGN-30"},{"type":"CASRegistryName","name":"775303-41-8"},{"type":"Synonym","name":"anti-CD30 monoclonal antibody"},{"type":"CodeName","name":"CAC-10"},{"type":"CodeName","name":"CAC10"},{"type":"CodeName","name":"SGN30"}],"definition":{"html":"A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.","text":"A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations."},"drugInfoSummaryLink":null,"nciConceptId":"C2007","nciConceptName":"Brentuximab","termId":357600,"name":"brentuximab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"brentuximab"},{"aliases":[{"type":"Synonym","name":"anti-CD30 antibody-drug conjugate SGN-35"},{"type":"Synonym","name":"anti-CD30 ADC SGN-35"},{"type":"Synonym","name":"antibody-drug conjugate SGN-35"},{"type":"CodeName","name":"SGN-35"},{"type":"USBrandName","name":"Adcetris"},{"type":"Abbreviation","name":"cAC10-vcMMAE"},{"type":"CASRegistryName","name":"914088-09-8"},{"type":"CodeName","name":"ADC SGN-35"},{"type":"Synonym","name":"anti-CD30 monoclonal antibody-MMAE SGN-35"},{"type":"Synonym","name":"anti-CD30 monoclonal antibody-monomethylauristatin E SGN-35"}],"definition":{"html":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","text":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin","text":"Brentuximab Vedotin"},"nciConceptId":"C66944","nciConceptName":"Brentuximab Vedotin","termId":530758,"name":"brentuximab vedotin","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"brentuximab-vedotin"}],"links":null}